Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on
the progression of severe non proliferative diabetic retinopathy, proliferative diabetic
retinopathy and active photocoagulated diabetic proliferative by evaluation of ischemic areas
and regression of retinal and disc neovasculrization.
Methods: 40 patients were enrolled in a prospective, interventional study. Patients were
treated with intravitreal bevacizumab 0.1ml (0.25mg). We evaluated visual acuity,
neovascularization leakage points, capillary closure ischemic areas and macular edema by
clinical examination and fluorescein angiography. A clinical examination was performed at
baseline and days 1,14 and 30. Active leakage points were measured by fluorescein angiography
at 30 days.